Key facts
- CuroVax’s last known valuation is $405.0M (Jan 2024).
- It has raised $74.2M; the latest was Later Stage VC ($47.2M) in Dec 2025.
- Notable investors include Qiming Venture Partners, Green Pine Capital Partners, Tailong VC, Hankang Capital, Beijing Jiurui Tiancheng Technology — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for CuroVax
- ·The full record, as it builds
Funding rounds
No funding rounds for CuroVax are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CuroVax
Manufacturer of human vaccine products and immunization technologies aims to advance global public health through innovative vaccine development. The company's offerings feature end-to-end capabilities in independent R&D, large-scale mammalian cell culture, antigen purification, mRNA vaccine platforms, and full-cycle GMP manufacturing across 41000 square meters of certified production space, helping healthcare providers and governments deliver safe and effective vaccines, enabling broad immunization coverage and improved global disease prevention.
- Sector
- Healthcare
- HQ
- Changzhou, China
- Founded
- 2011
- Employees
- 303
- Website
- curovax.net/
- Ownership
- Privately Held (backing)
CuroVax doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CuroVax shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CuroVax in its N-PORT filings yet. We sweep new filings monthly.